Head-To-Head Survey: Intensity Therapeutics (NASDAQ:INTS) versus Fulcrum Therapeutics (NASDAQ:FULC)

Intensity Therapeutics (NASDAQ:INTS) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility & Risk

Intensity Therapeutics has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.93, indicating that its stock price is 193% more volatile than the S&P 500.

Valuation and Earnings

This table compares Intensity Therapeutics and Fulcrum Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61 million	($5.71)	-0.72
Fulcrum Therapeutics	$80.00 million	3.16	-$74.88 million	($1.15)	-3.30

Intensity Therapeutics has higher earnings, but lower revenue than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Intensity Therapeutics and Fulcrum Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1	0	2	1	2.75
Fulcrum Therapeutics	4	7	1	0	1.75

Intensity Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 815.75%. Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 115.79%. Given Intensity Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Intensity Therapeutics is more favorable than Fulcrum Therapeutics.

Profitability

This table compares Intensity Therapeutics and Fulcrum Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

Insider and Institutional Ownership

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Intensity Therapeutics beats Fulcrum Therapeutics on 7 of the 13 factors compared between the two stocks.

About Intensity Therapeutics

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.